NTRK Genes and Cancer: when Arresting the Fusion Underlies the Treatment

References

• Miettinen M , Felisiak-GolabekA , LuiñaContreras Aet al. New fusion sarcomas: histopathology and clinical significance of selected entities. Hum. Pathol.86, 57–65 (2019).
   PubMed Web of Science ®Google Scholar
• Jiang T , WangG , LiuYet al. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm. Sin. B. S221138352030586411, 355–372 (2020).
   PubMed Web of Science ®Google Scholar
• Doebele RC , DrilonA , Paz-AresLet al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three Phase 1–2 trials. Lancet Oncol.21(2), 271–282 (2020).
   PubMed Web of Science ®Google Scholar
• Sigal D , TartarM , XavierMet al. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. J. Natl. Compr. Canc. Netw.15(11), 6 (2017).
   Web of Science ®Google Scholar
• Cocco E , ScaltritiM , DrilonA. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol.15(12), 731–747 (2018).
   PubMed Web of Science ®Google Scholar
• Hsiao SJ . Detection of tumor NTRK gene fusions to identify patients who may benefit from TRK inhibitor therapy. 21, 553–571
   Google Scholar
• Ricciuti B , GenovaC , CrinòL , LibraM , LeonardiGC. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. OncoTargets Ther.12, 3171–3179 (2019).
   PubMed Web of Science ®Google Scholar
• Chetty R . Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes. J. Clin. Pathol.72(3), 187–190 (2019).
   PubMed Web of Science ®Google Scholar
• Cocco E , ScaltritiM , DrilonA. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol.15(12), 731–747 (2018).
   PubMed Web of Science ®Google Scholar
• Lezcano C , ShoushtariAN , AriyanC , HollmannTJ , BusamKJ. Primary and metastatic melanoma with NTRK-fusions. 42(8), 1052–1058 (2019).
   Google Scholar
• Hsiao SJ . Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy. J. Mol. Diagn.21, 553–571
   PubMed Web of Science ®Google Scholar
• Shi E , ChmieleckiJ , TangC-Met al. FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors. J. Transl. Med.14(1), 1–11 (2016).
   PubMedGoogle Scholar
• uterine sarcomas.pdf
   Google Scholar
• Kheder ES , HongDS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin. Cancer Res.24(23), 5807–5814 (2018).
   PubMed Web of Science ®Google Scholar
• Torre M . Molecular and clinicopathologic features of gliomas harboring NTRK fusions. 8, 107 (2020).
   Google Scholar
• Kang J , ParkJW , WonJ-Ket al. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors. Diagn. Pathol.15(1), 114 (2020).
   PubMed Web of Science ®Google Scholar
• Solomon JP , LinkovI , RosadoAet al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod. Pathol.33(1), 38–46 (2020).
   PubMed Web of Science ®Google Scholar
• Marchiò C , ScaltritiM , LadanyiMet al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.30(9), 1417–1427 (2019).
   PubMed Web of Science ®Google Scholar
• Naito Y , MishimaS , AkagiKet al. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int. J. Clin. Oncol.25(3), 403–417 (2020).
   PubMed Web of Science ®Google Scholar
• Shulman DS , DuBoisSG. The evolving diagnostic and treatment landscape of NTRK-fusion-driven pediatric cancers. Pediatr. Drugs.22(2), 189–197 (2020).
   PubMed Web of Science ®Google Scholar
• Haratake N , SetoT. NTRK fusion-positive non-small-cell lung cancer - the diagnosis and targeted therapy-. Clin. Lung Cancer. S152573042030315622, 1–5 (2020).
   PubMed Web of Science ®Google Scholar
• Forschner A , ForchhammerS , BonzheimI. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications. JDDG J. Dtsch. Dermatol. Ges.doi:https://doi.org/10.1111/ddg.14160 (2020).
   Web of Science ®Google Scholar
• Drilon A , LaetschTW , KummarSet al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med.378(8), 731–739 (2018).
   PubMed Web of Science ®Google Scholar
• van Tilburg CM , DuBoisSG , AlbertCMet al. Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients. J. Clin. Oncol.37(suppl_15), 10010–10010 (2019).
   Google Scholar
• Federman N , McDermottR. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. Expert Rev. Clin. Pharmacol.12(10), 931–939 (2019).
   PubMed Web of Science ®Google Scholar
• Bayer . A Phase 2 basket study of the oral TRK inhibitor larotrectinib in subjects with NTRK fusion-positive tumors. https://clinicaltrials.gov/ct2/show/study/NCT02576431 (2021).
   Google Scholar
• Desai AV , RobinsonGW , BasuEMet al. Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. J. Clin. Oncol.38(suppl_15), 107–107 (2020).
   PubMed Web of Science ®Google Scholar
• Roche Hoffmann-La . An open-label, multicenter, global Phase 2 basket study of entrectinib for the treatment of patients with locally advanced or metastatic solid tumors that harbor NTRK1/2/3, ROS1, or ALK gene rearrangements. https://clinicaltrials.gov/ct2/show/study/NCT02568267 (2021).
   Google Scholar
• Yoshino T , PentheroudakisG , MishimaSet al. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann. Oncol.31(7), 861–872 (2020).
   PubMed Web of Science ®Google Scholar
• Naito Y , MishimaS , AkagiKet al. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int. J. Clin. Oncol.25(3), 403–417 (2020).
   PubMed Web of Science ®Google Scholar
• Bebb DG , BanerjiS , BlaisNet al. Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults. Curr. Oncol.28(1), 523–548 (2021).
   PubMed Web of Science ®Google Scholar
• Doebele RC , DrilonA , Paz-AresLet al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol.21(2), 271–282 (2020).
   PubMed Web of Science ®Google Scholar
• Okamura R , BoichardA , KatoS , SicklickJK , BazhenovaL , KurzrockR. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis. Oncol.2(2), 1–20 (2018).
   Google Scholar
• Amatu A , Sartore-BianchiA , SienaS. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open.1(2), e000023 (2016).
   PubMed Web of Science ®Google Scholar